Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis (PNE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01078753 |
Recruitment Status :
Completed
First Posted : March 2, 2010
Results First Posted : November 2, 2011
Last Update Posted : November 2, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nocturnal Enuresis | Drug: Desmopressin Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 89 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-blind, Placebo-controlled, Phase III Comparative Study With FE992026 in Children and Adolescents With Reduced Night-time Urinary Osmolarity-type Nocturnal Enuresis |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | September 2010 |
Actual Study Completion Date : | September 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Desmopressin
During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of <75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
|
Drug: Desmopressin
Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
Other Names:
|
Placebo Comparator: Placebo
Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
|
Drug: Placebo
Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime. |
- Change in the Number of Wet Nights Between Baseline and Treatment Period II [ Time Frame: Baseline (14-day period prior to starting study treatment) and Treatment Period II (weeks 3-4 after treatment initiation). ]The number of wet nights was recorded by participants (or their caregivers) in a daily diary. The difference was calculated from the number of wet nights during the 14-day Baseline Period minus the number of wet nights during the 14-day Treatment Period II.
- Change in Number of Wet Nights Between Baseline and Treatment Period I [ Time Frame: Baseline (14-day period prior to starting study treatment) and Treatment Period I (weeks 1-2 after treatment initiation). ]The number of wet nights was recorded by participants (or their caregivers) in a daily diary. The difference was calculated from the number of wet nights during the 14-day Baseline Period minus the number of wet nights during the 14-day Treatment Period I.
- Change in Number of Wet Nights Between Treatment Periods I and II [ Time Frame: Treatment Period I (weeks 1-2) and Treatment Period II (weeks 3-4) ]The number of wet nights was recorded by participants (or their caregivers) in a daily diary. The difference was calculated from the number of wet nights during the 14-day Treatment Period I minus the number of wet nights during the 14-day Treatment Period II.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 15 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed nocturnal enuresis with reduced nighttime urinary osmolality
- Age 6 or above but under 16 regardless of gender
- Out-patient
- Had 10 or more wet nights during the 14-day baseline period and at least 4 wet nights in each respective week
- Deemed healthy by the investigator
- Able to agree to and comply with fluid-intake restriction during the clinical trial and matters specified in the clinical trial protocol
- Consent from the pediatric patient's legally acceptable representative
- Demonstrate an understanding about this clinical trial after receiving an explanation corresponding to the prospective subject's intelligibility
- Show no possibility of being a nursing mother or pregnant, or becoming pregnant
- If under drug or medical therapy other than Desmopressin for treating nocturnal enuresis: able to discontinue such treatment
Exclusion Criteria:
- Suffer from enuresis with an underlying disease
- Participated in another clinical trial within six months preceding consent
- Used an intranasal Desmopressin in the past
- Presently undergoing a systemic antibiotic treatment, a treatment with an antidiuretic or a drug that affects urinary concentration, or a drug or medical therapy for overactive bladder
- Have an anomaly or a disease that may affect the oral absorption of drug products
- Hard to get cooperation from subject by school refusal, punishment or bullying
- Deemed by the investigator to be inappropriate to participate in this trial
- Unable to be placed on water-intake restriction starting from two hours before bedtime
- Evidence of hepatic, renal, cardiac, or pulmonary dysfunction

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01078753
Japan | |
Showa Hospital | |
Amagasaki, Hyogo, Japan | |
Shinko-Kakogawa Hospital | |
Kakogawa, Hyogo, Japan | |
Tamura Children's Clinic | |
Mito, Ibaraki, Japan | |
Shinbo Child Clinic | |
Yokohama, Kanagawa, Japan | |
Kansai Medical University Hirakata Hospital | |
Hirakata, Osaka, Japan | |
Takesue Children's Clinic | |
Musashino, Tokyo, Japan | |
Juntendo University Nerima Hospital | |
Nerima, Tokyo, Japan | |
Saitoh Pediatric Medical Clinic | |
Nishi-Tokyo, Tokyo, Japan | |
Hoashi Children's Psychological Clinic | |
Setagaya, Tokyo, Japan | |
Akita University Hospital | |
Akita, Japan | |
Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital | |
Hiroshima, Japan | |
Aikawa Station Clinic | |
Niigata, Japan | |
Kitano Hospital | |
Osaka, Japan | |
Saitama Childrens Medical Centre | |
Saitama, Japan | |
Shintoshin Child Clinic | |
Saitama, Japan |
Study Director: | Clinical Development Support | Ferring Pharmaceuticals |
Responsible Party: | Ferring Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01078753 |
Other Study ID Numbers: |
FE992026 CS35 |
First Posted: | March 2, 2010 Key Record Dates |
Results First Posted: | November 2, 2011 |
Last Update Posted: | November 2, 2011 |
Last Verified: | September 2011 |
Enuresis Urinary Incontinence Nocturnal Enuresis Urination Disorders Urologic Diseases Behavioral Symptoms Elimination Disorders Mental Disorders |
Lower Urinary Tract Symptoms Urological Manifestations Deamino Arginine Vasopressin Hemostatics Coagulants Antidiuretic Agents Natriuretic Agents Physiological Effects of Drugs |